From: Visfatin, glucose metabolism and vascular disease: a review of evidence
Medical Condition | Visfatin |
---|---|
Atherosclerosis | Increased serum levels [10, 31] Increased expression in instable plaques [31] |
Endothelial dysfunction | Increased serum levels [18] |
Cardioprotection | Reduces infarct area [36] |
Metabolic Syndrome | Controversial, Increased serum levels [34] |
Adiponectin | |
Hepatic Fat Disease | Diminished serum levels in steatohepatitis [16] Increased serum levels with progressive portal inflammation [17] |
Tumoral replication | Visfatin antagonist being tested [19] |
Acute lung injury | Increased serum levels [15] |
Renal insufficiency | Increased serum levels [18] |
Beta cell function impairment | |
Insulin resistance | |
Insulin-mimetic effect | |
Diabetes | |
Obesity | |
Visceral Fat | |
Vascular smooth muscle | Promotes inflammation [32] |